Breast/ovarian cancer
1 – 10 of 42
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
- PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma (
- Analysis of fusion transcripts indicates widespread deregulation of snoRNAs and their host genes in breast cancer (
- SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery (
- The mutational landscape of the SCAN‐B real‐world primary breast cancer transcriptome (
- Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer (
- Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers (
- Fine-tuning the metabolic rewiring and adaptation of translational machinery during an epithelial-mesenchymal transition in breast cancer cells (
- Defining the mutational landscape of 3,217 primary breast cancer transcriptomes through large-scale RNA-seq within the Sweden Cancerome Analysis Network: Breast Project (SCAN-B; NCT03430492). (
- CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients (
- Simvastatin is a potential candidate drug in ovarian clear cell carcinomas (